Healthy Skepticism Library item: 13569
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Jureidini JN, McHenry LB, Mansfield PR.
Clinical trials and drug promotion: Selective reporting of study 329
The International Journal of Risk and Safety in Medicine 2008 May; 20:(1-2):73-81
http://iospress.metapress.com/content/k36834543w9063rr/?p=8b89494c5d4c4f42946f75de3efdefa1&pi=6
Abstract:
Selective reporting is prevalent in the medical literature, particularly in industry-sponsored research. In this paper, we expose selective reporting that is not evident without access to internal company documents. The published report of study 329 of paroxetine in adolescents sponsored by GlaxoSmithKline claims that “paroxetine is generally well tolerated and effective for major depression in adolescentsâ€. By contrast, documents obtained during litigation reveal that study 329 was negative for efficacy on all 8 protocol specified outcomes and positive for harm.
Keywords:
Selective reporting, SSRI, litigation, industry sponsorship
Notes:
Full text at:
http://www.pharmalot.com/wp-content/uploads/2008/04/329-study-paxil.pdf
Documents available at:
http://healthyskepticism.org/documents/PaxilStudy329.php
